Statement of Changes in Beneficial Ownership (4)

Date : 03/20/2017 @ 3:13PM
Source : Edgar (US Regulatory)
Stock : Endonovo Therapeutics, Inc. (QB) (ENDV)
Quote : 0.068  0.005 (7.94%) @ 3:59PM

Statement of Changes in Beneficial Ownership (4)

FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Mann Michael Scott
2. Issuer Name and Ticker or Trading Symbol

ENDONOVO THERAPEUTICS, INC. [ ENDV ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
President
(Last)          (First)          (Middle)

6320 CANOGA AVENUE
3. Date of Earliest Transaction (MM/DD/YYYY)

2/28/2017
(Street)

WOODLAND HILLS, CA 91367
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   2/28/2017     P    1000   A $0.0181   19773649   D    
Common Stock   3/2/2017     P    1000   A $0.0148   19774649   D    
Common Stock   3/2/2017     P    1000   A $0.0149   19775649   D    
Common Stock   3/2/2017     P    1000   A $0.0163   19776649   D    
Common Stock   3/2/2017     P    2000   A $0.0163   19778649   D    
Common Stock   3/2/2017     P    1000   A $0.0171   19779649   D    
Common Stock   3/2/2017     P    2000   A $0.017   19781649   D    
Common Stock   3/3/2017     P    1000   A $0.0158   19782649   D    
Common Stock   3/3/2017     P    1000   A $0.0156   19783649   D    
Common Stock   3/3/2017     P    1000   A $0.0155   19784649   D    
Common Stock   3/3/2017     P    1000   A $0.0155   19785649   D    
Common Stock   3/3/2017     P    1000   A $0.0154   19786649   D    
Common Stock   3/7/2017     P    1000   A $0.0139   19787649   D    
Common Stock   3/7/2017     P    200   A $0.0144   19787849   D    
Common Stock   3/7/2017     P    200   A $0.0144   19788049   D    
Common Stock   3/7/2017     P    200   A $0.0145   19788249   D    
Common Stock   3/8/2017     P    200   A $0.0139   19788449   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Mann Michael Scott
6320 CANOGA AVENUE
WOODLAND HILLS, CA 91367

X President

Signatures
Michael Mann 3/20/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Endonovo Therapeutics, Inc. (USOTC:ENDV)
Historical Stock Chart

1 Year : From May 2016 to May 2017

Click Here for more Endonovo Therapeutics, Inc. Charts.

Endonovo Therapeutics, Inc. (USOTC:ENDV)
Intraday Stock Chart

Today : Friday 26 May 2017

Click Here for more Endonovo Therapeutics, Inc. Charts.

Latest ENDV Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.